Share This Author
Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease…
- A. Mastrolorenzo, S. Rusconi, A. Scozzafava, G. Bárbaro, C. Supuran
- Biology, MedicineCurrent medicinal chemistry
- 31 October 2007
A review on the pharmacology and interactions of these agents with other drugs is presented, with emphasis on how these pharmacological interferences may improve the clinical use of antivirals, or how side effects due to PI drugs may be managed better by taking them into account.
Anticancer and antiviral sulfonamides.
- A. Scozzafava, T. Owa, A. Mastrolorenzo, C. Supuran
- Biology, ChemistryCurrent medicinal chemistry
- 31 May 2003
The review summarizes recent classes of sulfonamides and related sulfonyl derivatives disclosed as effective tumor cell growth inhibitors, or for the treatment of different types of cancer.
Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.
- G. Bárbaro, A. Scozzafava, A. Mastrolorenzo, C. Supuran
- Biology, ChemistryCurrent pharmaceutical design
- 1 May 2005
A review on the pharmacology and interactions of these agents with other drugs is presented, with emphasis on how these pharmacological interferences may improve the clinical use of antivirals, or how side effects due to these drugs may be managed better by taking them into account.
Carbonic anhydrase inhibitors and activators and their use in therapy
Activation of mammalian CAs by various classes of activators intensively studied may ultimately lead to the design of pharmacologically useful derivatives for the enhancement of synaptic efficacy, which may represent a conceptually new approach for the treatment of depression, Alzheimer’s disease, ageing and other conditions in which spatial learning and memory therapy must be enhanced.
COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents.
- C. Supuran, A. Casini, A. Mastrolorenzo, A. Scozzafava
- Chemistry, BiologyMini reviews in medicinal chemistry
- 31 July 2004
It was recently shown that the sulfonamide COX-2 selective inhibitors (but not the methylsulfone ones) also act as nanomolar inhibitors of several isozymes of the metallo-enzyme carbonic anhydrase (CA), some of which are strongly involved in tumourigenesis.
Development and ex vivo evaluation of 5-aminolevulinic acid-loaded niosomal formulations for topical photodynamic therapy.
Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
- I. Nishimori, D. Vullo, A. Innocenti, A. Scozzafava, A. Mastrolorenzo, C. Supuran
- Chemistry, BiologyJournal of medicinal chemistry
- 29 October 2005
A lately discovered carbonic anhydrase (hCA, EC 18.104.22.168), the mitochondrial hCA VB, was cloned, expressed, and purified. Kinetic parameters proved it to be 3.37 times more effective than hCA VA as a…
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.
Antiviral sulfonamide derivatives.
- C. Supuran, A. Innocenti, A. Mastrolorenzo, A. Scozzafava
- Biology, ChemistryMini reviews in medicinal chemistry
- 31 January 2004
The sulfonamides constitute an important class of drugs, with several types of pharmacological agents possessing antibacterial, anti-carbonic anhydrase, diuretic, hypoglycemic, antithyroid and…
An update in the development of HIV entry inhibitors.
- S. Rusconi, A. Scozzafava, A. Mastrolorenzo, C. Supuran
- BiologyCurrent topics in medicinal chemistry
- 30 June 2007
Many HIV entry and fusion inhibitors are currently investigated in controlled clinical trials, and there are a number of them that is bioavailable as oral formulations, an essential feature for an extended use of these compounds with the purpose of ameliorating adherence of patients to these medications and preventing the development of drug resistance.